| Trial ID: | L0957 |
| Source ID: | NCT01364402
|
| Associated Drug: |
Epoetin Beta
|
| Title: |
Prevention of Contrast Induced Nephropathy by Erythropoietin
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Chronic Kidney Insufficiency
|
| Interventions: |
DRUG: Epoetin beta|DRUG: Saline 0.9%
|
| Outcome Measures: |
Primary: Incidence of Contrast Induced Nephropathy(CIN), 1-3 days after exposure to contrast media | Secondary: Enzymatic infarct size, Will be measured by Troponin and CK, 6h and 12 h after exposure to contrast media|Hospital length of stay, participants will be followed for the duration of hospital stay, an expected average of 3 days|Renal replacement therapy, participants will be followed after PCI procedure till discharge, an expected average of 1-2 days|Hospital mortality, participants will be followed after PCI procedure till discharge, an expected average of 1-2 days
|
| Sponsor/Collaborators: |
Sponsor: Western Galilee Hospital-Nahariya
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
142
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION
|
| Start Date: |
2011-08
|
| Completion Date: |
2013-12
|
| Results First Posted: |
|
| Last Update Posted: |
2012-10-10
|
| Locations: |
Western Galilee Hospital, Nahariya, Israel
|
| URL: |
https://clinicaltrials.gov/show/NCT01364402
|
